Catridecacog
| Clinical data | |
|---|---|
| Trade names | Tretten, NovoThirteen |
| ChemSpider | none |
Catridecacog (brand name Tretten in the US and NovoThirteen in Europe[1]) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.[2] It was brought to market by Novo Nordisk.[1]
References
- 1 2 NHS New Drugs Online Report for catridecacog Page accessed July 2, 2015
- ↑ Catridecacog: First drug to treat rare genetic blood clotting disorder. The Pharmacist February 01, 2014
See also
- Korte W (9 July 2014). "Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?". J Blood Med. 5: 107–13. doi:10.2147/JBM.S35395. PMC 4096448. PMID 25031548.
- Mozaffari S, Nikfar S, Abdollahi M (July 2015). "Inflammatory bowel disease therapies discontinued between 2009 and 2014". Expert Opin Investig Drugs 24 (7): 949–56. doi:10.1517/13543784.2015.1035432. PMID 25861835.
CNDO-210 and Catridecacog were discontinued due to safety concerns and lack of efficacy, respectively.
This article is issued from Wikipedia - version of the Friday, February 12, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.